We make affordable, accessible and safe medicines: for civilization diseases, and for treatments that save lives.
Researched, sourced, made and taken to market by one group, across the major therapeutic areas, sold in more than a hundred markets.
skus
2,000+
products in development
200+
Marketing Authorisations
1,000+
markets
100+
therapeutic areas
Our portfolio reaches from everyday chronic care to specialist oncology and immunology.
api & FDF
For 19 molecules, the Group makes both the active ingredient and the finished dosage form.
We have repeatedly been first to market with generic DMF filings, LOE launches, and EU respiratory products, while expanding into ophthalmics and building a growing patent portfolio. The company has also converted 15+ Rx products to CHC status and secured 15+ innovation patents.
Seventy active substances,
made in Europe.
the api portfolio
Forty-one commercial APIs in active production over cutting-edge technology platforms: cryogenic, hazardous chemistry, hi-potent, oligonucleotides, payloads and linkers, and solid state chemistry. A full DMF stack and an FDA-cleared European site, for partners moving supply out of India and China - from the only large-scale active-substance plant in Poland.
APIs
in portfolio
APIs
in commecial supply
Clean FDA cycles
since 2004
Almost every dosage form, across six manufacturing plants.
the fdf portfolio
Six manufacturing sites in Europe and Central Asia run technology platforms few Eureopean plants can manufacture: blow-fill-seal parenterals, cephalosphorin antibiotics, co-integrated inhalers, complex sterile and long-acting injectables, high-potent solids, preservative-free ophthalamics and soft gelatin capsules.
Tablets
per year
Capsoules
per year
Ampoules
per year
commercial types
The Group commercializes 2000 SKUs across two distinct commercial logics.
Rx to CHC switch
The same molecule, on prescription or off the shelf.
The Group clears its own switches, so the evidence a regulator asks for already exists. A partner can launch the same product on prescription in one market and off the shelf in another, without building that case from scratch.
pipeline composition
Our growth in each segment comes from a different source: launch timing, switched demand, manufacturing complexity, and new formulations.
Revenue share until 2025
€190M+
Cardio-diabetes sales, with more than 30 brands above €1m sales
€85M+
Anti-infective sales, with more than 20 brands above €1m sales
€80M+
Central nervous system sales, with more than 15 brands above €1m sales
€85M
Alimentary sales, with more than 15 brands above €1m sales
Group’s commentary
More than 85% of patent expiries covered in the Group's core markets, more than half across the top-five European markets, with over ten innovative combinations in cardiology.
Market Access
Polpharma Group reaches every market directly, or through partners.
In its core regions we sell through our own commercial companies; beyond them, we out-license to partners who market the products as their own.
ZF Polpharma
Polpharma Santo
Polpharma API
Polpharma CMO
Farmaprojects
089PHARM
Ziołolek
Polfa Lublin
intergrated value chain